Sugi Predict

Sugi Predict / Targets / CDK5

CDK5

Cyclin-dependent kinase 5 · Q00535 · CDK5 on Sugi Atlas →

208,778 patent compounds predicted against CDK5, 133,845 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Kenpaullone Kenpaullone (SCHEMBL79889) 1.00 17/20
Purvalanol B Purvalanol B (SCHEMBL27951) 1.00 14/20
Aloisine Aloisine (SCHEMBL79714) 1.00 14/20
SCHEMBL102235 SCHEMBL102235 1.00 13/20
SCHEMBL102955 SCHEMBL102955 1.00 13/20
SCHEMBL102656 SCHEMBL102656 0.79 13/20
SCHEMBL102951 SCHEMBL102951 0.76 13/20
SCHEMBL102660 SCHEMBL102660 0.75 13/20
SCHEMBL102233 SCHEMBL102233 1.00 12/20
SCHEMBL103266 SCHEMBL103266 0.82 12/20
SCHEMBL102507 SCHEMBL102507 0.78 12/20
SCHEMBL102984 SCHEMBL102984 0.77 12/20
SCHEMBL102650 SCHEMBL102650 0.76 12/20
SCHEMBL102952 SCHEMBL102952 0.76 12/20
Aloisine A Aloisine A (SCHEMBL80147) 1.00 11/20
SCHEMBL103265 SCHEMBL103265 1.00 11/20
SCHEMBL102236 SCHEMBL102236 0.75 11/20
SCHEMBL102764 SCHEMBL102764 0.75 11/20
SCHEMBL102225 SCHEMBL102225 0.72 11/20
SCHEMBL102239 SCHEMBL102239 0.70 11/20

Clinical trials — most relevant to CDK5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients PHASE3UNKNOWN
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy nanUNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
The Association Between Fever and CDKL5 Deficiency Disorder: a Nationwide Survey nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDK5 binder may also engage these)

ProteinNameSimilarity
Q03114 — 1.000 Q03114 →
P51166 — 1.000 P51166 →
Q2PQN9 — 1.000 Q2PQN9 →
Q02399 — 1.000 Q02399 →
P48609 — 1.000 P48609 →
P49615 — 1.000 P49615 →
P34117 — 0.999 P34117 →
Q4Z6R1 — 0.999 Q4Z6R1 →
Q5RCH1 — 0.999 Q5RCH1 →
Q9W739 — 0.998 Q9W739 →
CDK1 Cyclin-dependent kinase 1 0.998 landscape →
Q38774 — 0.998 Q38774 →
CDK2 Cyclin-dependent kinase 2 0.997 landscape →
P25859 — 0.997 P25859 →
P13863 — 0.997 P13863 →
Q9DGD3 — 0.996 Q9DGD3 →
Q9DGA5 — 0.996 Q9DGA5 →
P48963 — 0.996 P48963 →
Q9XZD6 — 0.996 Q9XZD6 →
Q6C7U8 — 0.996 Q6C7U8 →
P52389 — 0.995 P52389 →
Q9DGA2 — 0.995 Q9DGA2 →
Q8LG64 — 0.995 Q8LG64 →
O96821 — 0.994 O96821 →
P29619 — 0.994 P29619 →
P04551 — 0.994 P04551 →
Q4Y4B1 — 0.994 Q4Y4B1 →
Q26671 — 0.994 Q26671 →
P51958 — 0.993 P51958 →
O74456 — 0.993 O74456 →